Ventyx Biosciences, Inc. VTYX
Mar 6, 2026, 9:30 AM EST
52-week range unavailable
- YTD
- +55.04%
- 1 year
- +858.90%
- Market cap
- 1.00B
- YTD return
- +55.04%
- 1-year return
- +858.90%
- Volume
- 5.40M
- Open
- 14.00
- Previous close
- 14.00
- Day's range
- 14.00 – 14.00
- Earnings date
- Mar 5, 2026
2Y +5.05 (+56.42%)
Key statistics
- Enterprise value
- 982.56M
- PEG ratio
- -0.41
- Price / sales
- 0.00
- Price / book
- 5.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -24.86%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy0
- Buy0
- Hold5
- Sell0
- Strong sell0
Next earnings
Mar 5, 2026
Expected Mar 5, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 5, 2026 | Dec 30, 2025 | -0.38627 | — | — | — |
| Nov 6, 2025 | Sep 30, 2025 | -0.45 | -0.32 | +0.13 | +28.89% |
| Aug 7, 2025 | Jun 30, 2025 | -0.45 | -0.38 | +0.07 | +15.56% |
| May 8, 2025 | Mar 31, 2025 | -0.48 | -0.39 | +0.09 | +18.75% |
| Feb 27, 2025 | Dec 31, 2024 | -0.54 | -0.41 | +0.13 | +24.07% |
| Nov 7, 2024 | Sep 30, 2024 | -0.48 | -0.50 | -0.02 | -4.17% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 8, 2026 | Oppenheimer | down | Outperform | Perform |
| Jan 8, 2026 | Wells Fargo | down | Overweight | Equal-Weight |
| Jan 8, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| Jan 8, 2026 | UBS | down | Buy | Neutral |
| Jan 8, 2026 | LifeSci Capital | down | Outperform | Market Perform |
| Jan 8, 2026 | Canaccord Genuity | down | Buy | Hold |
About Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc. is a biopharmaceutical company in the clinical development phase, specializing in the creation of small molecule therapeutics for inflammatory and autoimmune disorders. The company's primary investigational drug, VTX958, a tyrosine kinase type 2 (TYK2) inhibitor, is currently undergoing Phase I clinical trials. This compound aims to address a range of immune-mediated conditions, including psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. Among its pipeline assets is VTX002, an oral sphingosine 1 phosphate receptor 1 (S1P1) modulator, which has advanced to Phase II clinical studies for the treatment of ulcerative colitis. Additionally, VTX2735, a peripherally targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor, is in Phase I development, intended to combat systemic inflammatory diseases affecting cardiovascular, hepatic, renal, and rheumatologic systems. Furthermore, Ventyx is engaged in the development of CNS-penetrant NLRP3 inhibitors, with the objective of providing therapies for neurological ailments such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. Founded in 2018, Ventyx Biosciences, Inc. is headquartered in Encinitas, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 81
- Website
- lilly.com
News
Ventyx Biosciences, Inc. Investigated by the Portnoy Law Firm 
JPMorgan Chase & Co. Has $2.33 Million Stock Holdings in Ventyx Biosciences, Inc. $VTYX 
Eli Lilly Expands Into Sleep Medicine With Centessa Buyout 
Ventyx Biosciences (NASDAQ:VTYX) Sees Strong Trading Volume – Here’s What Happened 
Contrasting Ventyx Biosciences (NASDAQ:VTYX) & Clene (NASDAQ:CLNN) 
Ventyx Biosciences, Inc. $VTYX Shares Sold by Cibc World Market Inc. 
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Consensus Recommendation of “Reduce” from Brokerages 
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX 
Halper Sadeh LLC Encourages STEL, GORO, SKYT, VTYX Shareholders to Contact the Firm to Discuss Their Rights 
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX
Your note
Sign in to keep a note on VTYX — it syncs with the Stock Master app.